Revision as of 23:46, 12 September 2010

Maternal serum alpha-fetoprotein

Introduction

brief outline on what will be covered

Background information

Maternal Serum Alpha Fetoprotein (MSAFP) screening is an non-invasive procedure in which the mother’s blood is taken and alpha-fetoprotein levels are measured. It is usually carried out during the 2nd trimester and is used to detect abnormalities such as neural tube defects, more specifically anencephaly spina bifida,encephalocele, open ventral wall defects such as gastroschisis as well as Down’s Syndrome.

What is Alpha fetoprotein

type of protein, structure, function, how and where is it made.

Alpha-Fetoprotein (AFP) is an embryo specific glycoprotein which is produced during the early stages of development by the liver, yolk sac as well as a small amount being produced by the gastrointestinal tract. AFP in adults is functionless as levels decrease drastically after birth with very low traces of AFP found in the average older adult with the only women experiencing spikes occurring in AFP levels during the onset of pregnancy and it is in fact through the testing of the blood of pregnant women, that AFP levels can be measured. The function of AFP itself is unknown but due to its similarity to albumin it has been hypothesized that AFP could be a carrier protein or may even play a role in the metabolism of bilirubin. Furthermore, it has been observed that it does play a role in the embryonic and early fetal stages of development as fluctuating levels of AFP indicate the presence of abnormalities within a fetus.

AFP has a molecular weight of around 70,000 daltons and is a single chain alpha globulin that has 590 amino acids and is estimated to have a 5% make up of carbohydrate content. It should be noted that it has an uncanny resemblance to another protein called albumin. The AFP level in human fetal serum is highest during the 13th week of gestation, where it may reach the level of several mg per ml, and accounts for almost a third of the total serum protein. Normal human serum also contains traces of AFP, however fetal AFP level is almost one million times higher than the adult level.

Ranges and Levels

AFP blood test ranges will vary between groups of people when factors such as age and sex come into play. However, a general trend for normal AFP levels in people is as follows:

Men: 0 - 20 ng/mL

Women: 0 - 20 ng/mL

Women (Pregnant): 7 - 124 ng/mL (depending on when the test was taken during weeks 15-22)

AFP in Pregnancy

Highest maternal AFP concentration occurs in the mid third trimester of the pregnancy where the mean level is 150-250ng/ml. The concentration of AFP in maternal serum at any moment of gestation development seems to be related to the AFP level in the fetal circulation as well as in the placental size.

Instances of abnormal AFP values (too high as well as too low) can partly been explained by physiological deviations from the expected normal pregnancy eg. in cases of under- or overestimated gestational age and multiple pregnancies. In other instances it have been found to indicate the presence of various fetal morphogenetic defects, such as open NTD (neural tube defect), hereditary congenital nephrosis (Finnish type), omphalocele, pilonidal sinus, esophageal atresia, and others.

The maternal AFP level has often reported to be increased in pregnancies where the fetus has a neural tube defect.

The Optimal practical time for detecting open spinabifida by measuring materal serum AFP is at 16-18 comepleted weeks of pregnancy. In Wald et el. (1977)’s sample of patients, 88% of cases of anencephaly, 79% of cases of open spina bifida, and 3% of unaffected singleton pregnancies had maternal serum AFP levels equal to or greater than 2.5 times the normal median. Because there is a certain degree of overlapping between the maternal AFP levels in pregnancies with and without fetal NTD, the AFP estimation in materal serum cannot per se serve as a specific diagnostic test, but it seems to be a useful screening test so as to select certain symptom-free women for further diagnostic procedures such as ultrasonography, amniocentesis, and amniography.

Maternal Serum Alpha Protein as a Screening Test

It should be made clear that MAFP is not a diagnostic test and is used only for screening purposes with further testing always necessary for any sort of accurate diagnosis to take place. Furthermore, MAFP is a screening test that is carried out during the second trimester whereas other tests may be carried out during the first trimester and are more accurate. It is part of two tests, one called the Triple Screen Test which is a battery of tests that measure AFP levels as well as human chorionic gonadotropin (hCG) and unconjugated estriol uE3 and a second series of tests known as the Quadruple Screen Test that tests AFP, hCG, uE3 as well as Inhibin A which is a hormone that is released by the placenta. These tests also take into account age, ethnic background, weight as well as the babys' gestational age.

Currently, there are no known risks or side effects that have been associated with the MSAFP screening test except for any discomfort involved with the drawing of blood from the patient.

Previously, the use of MSAFP as a screening test was called into question in regards to its accuracy as well as its cost effectiveness as a medical program from the perspective of a managed health care system (note that this was from the view of an American health insurer). It was concluded that MSAFP would not result in a cost savings to the insurer however, it would be cost-justified when viewed from the perspective of society when other reasonable assumptions where taken into account. In Australia, the MSAFP screening test isn't as commonly used as other first trimester tests however, it is one of the few pre-natal tests that is covered by medicare whereas all the first trimester tests available are payed by the patients themselves.

Disorders that MSAFP indicates

Spina bifida and Anencephaly which are neural tube defects where the neural tube fail to close properly. When the neural tube fails to close at the cranial end is call anencephaly whilst failure to close at the caudal end is call spina bifida.

MSAFP level testing is good for detection for spinal bifida and anencephaly. While ultrasonic examination is capable of diagnosing anencephaly in utero, it is unlikely to be widely available as a screening procedure for all pregnant women, and there is no satisfactory way of diagnosing spina bifida in early pregnancy. AFP estimations can be performed early in pregnancies without the knowledge of the outcomes of the pregnancies. In Wald’s study (1974) it was found that the pregnancies which turn out to have either spina bifida or anencephaly have a higher level of MSAFP than those in the control pregnancies matched for maternal age, parity, and length of gestation. Even though it is impossible to say with complete confidence that a fetus is unaffected if the MSAFP did not rise above normal levels, by measuring the maternal serum AFP levels we can say with a defined degree of confidence the likelihood of a pregnancy leading to spina bifida or anencephaly.

Accuracy

accuracy of the test, compare the test accuracy to other tests, statistcal information.

In regards to accuracy of test results, the triple screen test is known to have a high percentage of false positive results

- note that 1st trimester tests are generally have a higher detection rate than MSAFP tests that are done in the 2nd trimester - currently in most hospitals in australia, MSAFP is not actually carried out, instead, tests such as neuchal translucent tests amnio, etc.. are used. However, 1st trimester tests cost money whereas 2nd trimester tests which the MSFAP test falls under, are covered by health care and thus the individual is not required to pay themselves

Other instances where maternal serum AFP levels are elevated includes:

1) Fetus effected by hereditary cogenital nephrosis of the Finnish type - an hereditary, autosomal recessive disease which leads to death in early infancy.

2) Meckel syndrome early enough in gestation to permit termination

3) Intrauterine death

4) Multiple gestations such as twin pregnancies or triplets

In conclusion, aberrant AFP values in maternal serum samples are to be regarded as unspecific warning signals, which sometimes may be observed weeks in advance of any other clinical or biochemical symptom of a deviant fetal development. Therefore, more specific diagnostic measures must be employed to verify and characterize the type of pregnancy disturbance that may exist. Nevertheless, the determination of AFP in maternal serum provides valuable information concerning the progress of pregnancy. All pregnant women having had a neural tube defect fetus before should be offered determination of amniotic fluid AFP at about the 16th week of gestation.

conclusion

--Mark Hill 01:43, 5 August 2010 (UTC) You can now put your group discussion here. Here is the code to set up a search of PubMed Books - Prenatal Diagnosis and to Search Pubmed Now - Prenatal Diagnosis

References

Nadel A. S, MD. Green J.K. Holmes L.B, MD. Frigoletto F.D,Jr,MD. Benacerraf B.R, MD. The New England Journal of Medicine; Absence of need for amniocentesis in parents with elevated levels of maternal alpha fetoprotein and normal ultrasonographic examinations. Volume 323 August 30, 1990.

Wald N.J., Cuckle H, Brock J.H., Peto R, Polani P.E., Woodford F.P. (1977). Report of the UK Collaborative Study on Alpha-Fetoprotein in Relation to Neural-Tube Defects: Maternal serum-alphafetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Lancet, 1, 1323

2010 ANAT2341 Group Projects

Glossary Links

Glossary: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Numbers | Symbols | Term Link

Cite this page: Hill, M.A. (2024, April 24) Embryology 2010 Group Project 6. Retrieved from https://embryology.med.unsw.edu.au/embryology/index.php/2010_Group_Project_6

What Links Here?

@@ Line 67: / Line 67: @@
 '''Spina bifida and Anencephaly''' which are neural tube defects where the neural tube fail to close properly. When the neural tube fails to close at the cranial end is call anencephaly whilst failure to close at the caudal end is call spina bifida.
-This test is good for detection for spinal bifida and anencephaly. While ultrasonic examination is capable of diagnosing anencephaly in utero, it is unlikely to be widely available as a screening procedure for all pregnant women, and there is no satisfactory way of diagnosing spina bifida in early pregnancy. AFP estimations can be performed early in pregnancies without the knowledge of the outcomes of the pregnancies. In Wald’s study (1974) it was found that the pregnancies which turn out to have either spina bifida or anencephaly have a higher level of maternal serum AFP than those in the control pregnancies matched for maternal age, parity, and length of gestation. Even though it is impossible to say with complete confidence that a fetus is unaffected if the maternal serum AFP did not rise above normal levels, by measuring the maternal serum AFP levels we can say with a defined degree of confidence the likelihood of a pregnancy leading to spina bifida or anencephaly.
+MSAFP level testing is good for detection for spinal bifida and anencephaly. While ultrasonic examination is capable of diagnosing anencephaly in utero, it is unlikely to be widely available as a screening procedure for all pregnant women, and there is no satisfactory way of diagnosing spina bifida in early pregnancy. AFP estimations can be performed early in pregnancies without the knowledge of the outcomes of the pregnancies. In Wald’s study (1974) it was found that the pregnancies which turn out to have either spina bifida or anencephaly have a higher level of MSAFP than those in the control pregnancies matched for maternal age, parity, and length of gestation. Even though it is impossible to say with complete confidence that a fetus is unaffected if the MSAFP did not rise above normal levels, by measuring the maternal serum AFP levels we can say with a defined degree of confidence the likelihood of a pregnancy leading to spina bifida or anencephaly.

2010 Group Project 6: Difference between revisions